Brief: Biosergen Q4 EBITDA Loss Widens To SEK 12.5 Mln
31/03/2023 10:45
March 31 (Reuters) - Biosergen AB BIOSGN.ST :
* Q4 EBITDA LOSS SEK 12.5 MILLION VERSUS LOSS SEK 9.9
MILLION YEAR
AGO
* Q4 OPERATING LOSS SEK 12.5 MILLION VERSUS LOSS SEK 9.9
MILLION
YEAR AGO
* Q4 NET LOSS SEK 12.4 MILLION VERSUS LOSS SEK 10 MILLION
YEAR AGO
* BIOSERGEN PUBLISHES INTERIM REPORT FOR Q4 2022
Source text for Eikon: ID:nWkr1DsJ7c
Further company coverage: BIOSGN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million